Dr. Behbahani joined NEA’s healthcare team in 2007 and specializes in healthcare investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University.

Dr. Kadhiresan has more than a decade of operational experience in various functional roles including research, product development, and business development. Before joining JJDC, as head of Business Development at Guidant, Inc., now Boston Scientific, Inc., Dr. Kadhiresan led several transactions to access novel medical device technologies with venture investments, M&As, licensing and joint ventures. Prior to entering business development, he led the research and development of multiple early-stage technologies and products in cardiac rhythm management and heart failure. Dr. Kadhiresan was instrumental in the development of the cardiac resynchronization therapy for heart failure, now a multi-billion dollar worldwide market. At Heart Rhythm Technologies, a subsidiary of Guidant, he led the development of an ablation technology for treatment of atrial fibrillation and raised venture financing for the project. In addition, Dr. Kadhiresan is an inventor on more than 40 patents and has published several articles in peer-reviewed journals.

Dr. Kadhiresan received a PhD and Master of Science in Biomedical Engineering from the University of Michigan, Ann Arbor, a Master of Business Administration from the Kellogg School of Management at Northwestern University, and a Bachelor of Science in Electrical Engineering from the National Institute of Technology (REC), Trichy, India.

John M. Nehra graduated from the University of Michigan, BA 1970. Upon graduating, he joined Doyle O’Connor & Company, a leading nationwide NASDAQ trading firm based in Chicago, as an Associate in their Venture Group. In 1971 Mr. Nehra built a small Research and Sales Department following small to medium sized publicly traded growth stocks, complementing the firm’s historic trading capabilities. With the passing of Bob Doyle in 1975, the firm never fully realized its full potential.
In 1975 Alex Brown & Sons hired Mr. Nehra to build a corporate strategy in Health Care, with an expanded approach to Investment Banking. For decades Alex. Brown became the preeminent national firm in Health Care Research, Trading and Banking. Alex. Brown adopted this strategic template in Software, Transportation, Consumer and Financial Services. In 1981 Mr. Nehra became a Partner of the firm. Mr. Nehra also worked with Alex Brown’s Partners with an entry into Venture Capital, Merchant Banking and Capital Markets. Mr. Nehra worked and managed Health Care related Research and Investment Banking ultimately managing the Capital Markets Desk.
In 1989 until his retirement in August 2014, Mr. Nehra was affiliated with New Enterprise Associates (“NEA”), a leading venture capital firm, including, from 1993 until his retirement, as General Partner of several of its affiliated venture capital limited partnerships. Mr. Nehra also served as Managing General Partner of Catalyst Ventures, a venture capital firm, from 1989 to 2013. Mr. Nehra served on numerous boards of NEA’s portfolio companies in healthcare and technology until his retirement in August 2014. Mr. Nehra remains a retired special partner of NEA. Since 1999 Mr. Nehra has served on the board of DaVita (NYSE:DVA). He advises and is on the board of several private companies. He has been active with the Baltimore School for the Arts and various charities. Mr. Nehra is married and has two daughters.

Geoff Pardo joined Gilde Healthcare in 2011 as a Partner working out of the office in Boston/Cambridge, MA and is focusing on Gilde’s investments in North America. He led the investments in CVRx^®, InovaLabs (acquired by ResMed), BionX and Vapotherm and represents Gilde as a member of the board of directors for each company.

Previously, he was a Partner at Spray Venture Partners where he led investments into Interlace Medical (sold to Hologic), Solace Therapeutics, TearScience and Cascade Ophthalmics. He served on the board of Solace, TearScience and Cascade, and was actively involved in Interlace and Conventus Orthopedics.

Geoff also served as President & CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. He has also worked at Cardinal Partners as an Associate leading their investing activity in the medical device sector. He was responsible for sourcing and managing investments in Replication Medical and CardioOptics.

Geoff began his career in medical devices as a product manager with Synthes USA.

He has a B.A. with honors in History from Brown University and an M.B.A. from the Wharton School of Business. He is a US citizen based in Gilde Healthcare’s Cambridge, MA office.

Mr. Slattery serves on the Board of Exosome Diagnostics,Replimune Group, Inc., and CVRx^®. He has served as the Executive Vice President and Chief Financial Officer of TransEnterix, Inc. since October 2013. Previously, Mr. Slattery served as Executive Vice President and Chief Financial Officer of Baxano Surgical, Inc., a minimally invasive spine company, from April 2010 until September 2013. Mr. Slattery served as a member of the Baxano Surgical Board of Directors from November 2007 until April 2010 and resigned in connection with his appointment as an officer. From February 1996 through August 2007, Mr. Slattery served in various roles of increasing responsibility at Digene Corporation, a molecular diagnostics company that was acquired by Qiagen, N.V. in August 2007, including from October 2006 through August 2007 as Chief Financial Officer and Senior Vice President of Finance and Information Systems. Mr. Slattery served on the Board of Directors of Micromet, Inc., a publicly-held biopharmaceutical company, which was acquired by Amgen in March 2012. Mr. Slattery received a B.S. degree in Accountancy from Bentley University and is a Certified Public Accountant.

Nadim Yared is the President and Chief Executive Officer of CVRx^®. Mr. Yared had previously served as Vice President and General Manager of Medtronic Navigation, the leading supplier of integrated image-guided surgery products in the world, from 2002 – 2006. He also worked at GE Medical for 10-years, where he had been Vice President of Global Marketing for the OEC Medical Systems and Vice President and General Manager of GE’s European X-ray business based in Paris. Mr. Yared has an engineering degree from Ecole Nationale Supérieure des Télécommunications, and an MBA from INSEAD, France. Mr. Yared is a member of the Board of Directors for AdvaMed, MDIC, and CVRx^®. In addition, Mr. Yared has recently served as the Chairman of the AdvaMed Accel Board and he is currently the chairman of the AdvaMed Board of Directors. This is the first time that the CEO of a small company has become chairman of the AdvaMed Board of Directors in the 41 years of existence of the organization. Finally, Mr. Yared is one of the “100 people to know in 2017”, according to Minneapolis’ Twin Cities Business Magazine.

Nadim Yared is the President and Chief Executive Officer of CVRx^®. Mr. Yared had previously served as Vice President and General Manager of Medtronic Navigation, the leading supplier of integrated image-guided surgery products in the world, from 2002 – 2006. He also worked at GE Medical for 10-years, where he had been Vice President of Global Marketing for the OEC Medical Systems and Vice President and General Manager of GE’s European X-ray business based in Paris. Mr. Yared has an engineering degree from Ecole Nationale Supérieure des Télécommunications, and an MBA from INSEAD, France. Mr. Yared is a member of the Board of Directors for AdvaMed, MDIC, and CVRx^®. In addition, Mr. Yared has recently served as the Chairman of the AdvaMed Accel Board and he is currently the chairman of the AdvaMed Board of Directors. This is the first time that the CEO of a small company has become chairman of the AdvaMed Board of Directors in the 41 years of existence of the organization. Finally, Mr. Yared is one of the “100 people to know in 2017”, according to Minneapolis’ Twin Cities Business Magazine.

Mr. Brintnall has 38 years of business experience and has been the head of finance at six emerging growth companies (three in technology and three in medical devices) including Computer Network Technology, Integ, and Survivalink. John has an undergraduate degree in Finance from the University of Notre Dame.

Ms. Liz Galle has over 20 years of cardiovascular clinical trial experience.  Prior to coming to CVRx^®, she lead statistical and clinical scientist groups at Guidant (Boston Scientific Cardiac Rhythm Management) and was involved in the Women’s Health Initiative Study while at the Fred Hutchinson Cancer Research Center.  Liz earned a masters degree in biostatistics from Yale University School of Public Health.

Mr. Bruhn-Ding has over 33 years of experience in the medical device industry. He has held positions at St. Jude Medical, Guidant and Angeion in research, product development, regulatory affairs, quality assurance, and clinical affairs.  Most recently prior to CVRx^®, Dean was the Vice President of Regulatory Affairs for St. Jude Medical (SJM), Cardiology Division and held other Vice President and Director positions at the SJM Daig Division in Regulatory Affairs, Clinical Affairs, and Quality Assurance. Dean earned his undergraduate degree in Medical Technology from North Dakota State University.

Craig Palmer is the Vice President of US Commercial and Clinical Trial Market Development, possessing over 20 years of pharmaceutical, bio-technology, and cardiovascular medical device field experience. Prior to joining CVRx^®, Mr. Palmer was responsible for launching and developing the markets for key cardiovascular therapies, such as Carvedilol, Ranolazine, Implantable Cardiac Defibrillators, Pacemakers, and Cardiac Resynchronization Therapies. After graduating with a Bachelor of Science from The Pennsylvania State University, Mr. Palmer has had the privilege of working with some of the elite organizations of the industry, including GlaxoSmithKline, Gilead, Boston Scientific, and St. Jude Medical.